Article Text

PDF
THU0225 The Induction of Antinuclear Antibodies in Spondyloarthritis Patients Under Anti-TNF Alpha: A New Outcome Predictor?
  1. R. Fonseca,
  2. R. Vieira,
  3. P. Madureira,
  4. D. Rosa-Gonçalves,
  5. F. Aguiar,
  6. T. Rocha,
  7. A. Bernardo,
  8. E. Mariz,
  9. M. Bernardes,
  10. L. Costa
  1. Rheumatology, São João Hospital Centre, Porto, Portugal

Abstract

Background The induction of auto-antibodies, such as anti-nuclear antibodies (ANA), is a well-known phenomenon during anti-TNF alpha treatment. However, the correlation of this increase in ANA production and clinical response to anti-TNFα in Spondyloarthritis (Spa) patients is not yet determined.

Objectives To determine the impact of positivity for ANA (at baseline and after treatment) in clinical response and persistency of anti-TNFα treatment in Spa patients.

Methods Observational retrospective cohort study was performed. Patients fulfilling ASAS criteria for axial Spa, who started their first anti-TNFα between 2002 and 2013, and had performed serial ANA testing, were included. Disease activity (assessed with Bath Ankylosing Spondylitis Disease Activity - BASDAI and Ankylosing Spondylitis Disease Activity Score - ASDAS), clinical response (evaluated by ASDAS) and ANA testing (cut off titter >1/100) were collected at baseline and 6, 12, 18, 24 months (M) and in the last visit. Data were obtained by consulting Rheumatic Diseases Portuguese Register - Reuma.pt. Statistical analyses were performed using t-test, Mann-Whitney U-test, Chi-square and McNemar test (SPSS 21.0).

Results Among 129 Spa patients treated with anti-TNFα in our department, 104 patients (62.5% male, mean age 44.9 years (SD 11.6)) were included. The median follow-up time for this cohort was 3 years [1-11.5]. At baseline, ANA were detected in only 4 patients (3.8%). Disease activity parameters (BASDAI and ASDAS), ASDAS response or global drug discontinuation rate were similar between ANA positive and ANA negative patients at baseline.

We found a seroconversion rate for ANA of 45.2% (n=47) with median time of 22 months [0-86]. Infliximab group demonstrated higher ANA seroconversion rate (66.7%, n=18) compared with adalimumab (46.5% n=20), etanercept (33.3%, n=7) and golimumab (15.4% n=2) (p=0,012).

The patients that had increased ANA after treatment showed smaller median changes in BASDAI at 18M (2.2 vs 3.75, p=0.036) and at 24M (2.45 vs 3.9, p=0.04). The changes in ASDAS, in absolute value, were also smaller at 18 and 24 M (1.4 vs 2.2, p=0,023 and 1.8 vs 2.2, p=0.04 respectively) in these patients. No statistically significant differences were observed in ASDAS response at 6 and 12M. However, at 18M and 24M after treatment there was a higher rate of non-response in ANA positive patients (42,4% vs 22,5% p=0.027 and 36,8% vs 13,8% p=0.01 respectively). No significant differences in drug discontinuation rate due to al causes were found, between the two groups.

Conclusions We found a meaningful ANA seroconversion in Spa patients after anti-TNFα treatment. This study suggests that the increase of ANA after anti-TNFα treatment in Spa patients may affect clinical response with worse outcomes.

Disclosure of Interest None declared

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.